本文選題：慢性腎臟病 + 腎性貧血　； 參考：《廣西醫(yī)科大學》2014年碩士論文

【摘要】：目的探討慢性腎臟病患者心血管并發(fā)癥情況,及貧血、超敏C反應蛋白對慢性腎臟病心血管并發(fā)癥的影響。 方法收集2010年3月至2013年7月期間在南寧市第一人民醫(yī)院腎內(nèi)科住院的942例慢性腎臟病腎性貧血患者的臨床及實驗室資料。 結果1、942例慢性腎臟病腎性貧血患者中,CKD1期患者16例(1.70%)、CKD2期患者42例(4.46%)、CKD3期患者174例(18.47%)、CKD4期患者153例(16.42%)、CKD5期患者557例(59.13%)；CKD1-5期患者血紅蛋白均值分別為100.13±11.45g/L、99.21±13.34g/L、98.88±11.65g/L91.53±13.90g/L、78.94±18.02g/L。2、慢性腎臟病患者冠狀動脈疾病(CAD)、左心室肥厚(LVH)、充血性心力衰竭(CHF)、腦卒中(CVA)、大血管動脈粥樣硬化性疾病(LAD)的患病率分別為31.25%、54.76%、58.05%、60.78%、65.88%,其中CKD1-5期各組間CAD、LVH、CHF的患病率增加(P0.01),CVA、LAD的患病率無統(tǒng)計學差異。3、將貧血分為輕度、中度、重度3組,隨著貧血的加重,CAD、LVH患病率增加(P0.01),而CHF、CVA、LAD的患病率無統(tǒng)計學差異。4、按hs-CRP水平分為低危組(hs-CRP1.0mg/L)、中危組(1.0mg/L≤hs-CRP≤3.0mg/L)、高危組(hs-CRP3.0mg/L),3組間CAD、LVH、CHF、CVA、LAD的患病率均有所增加,有統(tǒng)計學差異(P0.05)。 結論：1、隨著腎功能的下降,貧血程度逐漸加重。2、腎功能下降增加CAD、LVH、CHF的患病率,對CVA、LAD影響無統(tǒng)計學差異。3、慢性腎臟病患者隨著貧血的加重,CAD、LVH的患病率增加。4、慢性腎臟病患者隨著hs-CRP升高,心血管并發(fā)癥(CAD、LVH、CHF、CVA、LAD)患病率增加。
[Abstract]:Objective to investigate the cardiovascular complications in patients with chronic kidney disease and the effects of anemia and hypersensitive C reactive protein on cardiovascular complications in patients with chronic kidney disease. Methods the clinical and laboratory data of 942 patients with renal anemia of chronic kidney disease were collected from March 2010 to July 2013 in Nanning first people's Hospital. Results among 1942 patients with renal anemia of chronic kidney disease, 16 (1.70%) were in CKD1 stage, 42 (4.46%) in CKD2 stage, 174 (18.47%) in CKD3 stage, 153 (16.42%) in CKD4 stage and 557 (59.13%) in CKD5 stage. The mean hemoglobin values of CKD1-5 patients were 100.13 鹵11.45g / L 99.21 鹵13.34g / L 91.53 鹵13.90g / L 91.53 鹵13.90g / L 78.94 鹵18.02g / L, respectively. The prevalence of CKD1-5 was 60.7888 in patients with chronic renal disease, left ventricular hypertrophy (LVH), congestive heart failure (CHF), stroke (CVA), and major atherosclerotic disease (lad). There was no significant difference in the prevalence of CADV LVHV CHF among the three groups (P0.01), and anemia was classified as mild. The prevalence of LVH increased with the exacerbation of anemia (P0.01), but there was no significant difference in the prevalence of CHFV-CVALAD. According to the level of hs-CRP, it was divided into low risk group (hs-CRP 1.0 mg / L), moderate risk group (1.0 mg / L 鈮，

本文編號：2092561